BCMA AS A TARGET FOR T CELL REDIRECTING ANTIBODIES IN B CELL LYMPHOMAS
Provided are methods for treating non-Hodgkin lymphoma (NHL) in a human subject comprising administering to the subject a therapeutically effective amount of a BCMA-specific antibody. Also disclosed are compositions comprising a BCMA-specific antibody in an amount that is therapeutically effective for treating non-Hodgkin lymphoma (NHL) in a human subject, and a γ-secretase inhibitor
1 . A method for treating non-Hodgkin lymphoma (NHL) in a human subject comprising administering to the subject a therapeutically effective amount of a BCMA-specific antibody.
2 . The method of claim 1 , wherein the BCMA-specific antibody is monospecific or bispecific.
3 . The method of claim 1 wherein the BCMA-specific antibody is teclistamab.
4 . The method of claim 1 wherein the non-Hodgkin lymphoma is a subtype characterized by expression of B cell maturation antigen (BCMA).
5 . The method of claim 1 wherein the non-Hodgkin lymphoma is chronic lymphocytic leukemia (CLL), lymphoblastic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, or Waldestrom macroglobulinemia
6 . The method of claim 1 wherein the subject is an adult.
7 . The method of claim 1 , wherein the amount of teclistamab that is administered to the subject is effective to activate T cells in the subject, induce neutrophil degranulation in the subject, induce cytokine production in the subject, or any combination thereof
8 . The method of claim 1 , further comprising administering to the subject a γ-secretase inhibitor.
9 . The method according to claim 8 , wherein the BCMA-specific antibody and the γ-secretase inhibitor are administered to the subject in a single dosage form.
10 . The method according to claim 8 , wherein the BCMA-specific antibody is administered in a first dosage form and the γ-secretase inhibitor is administered in a second dosage form.